Strengthening the Biochemistry and Immunoassay Testing Portfolio Through the Acquisition of Nippon Denshi's Medical Equipment Business
First written in FY2026-H1. 3 of 5 entries say "Achieved", first in 2026-05-14. Latest entry: 2026-08-07.
No other company in this theme has enough history to compare yet.
- 2026-08-07Cited as achievedEarnings
「In domestic sales, revenue in fields including clinical chemistry increased following the start of operations of Sysmex BioMajesty Co., Ltd., acquired from JEOL Ltd.」
Following the acquisition of JEOL Ltd.'s medical equipment business, the start of operations of Sysmex BioMajesty Co., Ltd. was reflected in higher domestic revenue in the first quarter. - FY2026AchievedAnnual report
「Under the agreement, JEOL transferred the Target Business to the newly established company, 株式会社医用機器事業分割準備会社, through an absorption-type company split, after which we acquired all shares of the company on 1 April 2026. In connection with the share acquisition, the company changed its corporate name to Sysmex BioMajesty Corporation.」
We completed the acquisition of all shares of the company holding JEOL Ltd.’s medical equipment business on 1 April 2026 and began operating the business as Sysmex BioMajesty Corporation. - FY2026-H1First statedAnnual report
「We resolved to acquire the medical equipment business of JEOL Ltd. (the “Target Business”) and entered into a share transfer agreement on 2 September 2025. JEOL will transfer the Target Business to a newly established company through an absorption-type company split, after which we plan to acquire all shares of the company and make it a subsidiary. Subject to the completion of various procedures and approvals from the relevant authorities, the share transfer is scheduled to be completed in April 2026.」
We plan to acquire all shares of the new company following the absorption-type company split of JEOL Ltd.’s medical equipment business, with completion of the share transfer scheduled for April 2026. The transaction is intended to strengthen biochemical automated analyzers, including BioMajesty, the biochemical and immunoassay fields, the reagent business, and global sales and customer care.